La aspirina en la prevención primaria del cáncer colorrectal
Palabras clave:
0Resumen
La Aspirina y otros antiinflamatorios (AINEs) se han asociado a una reducción en el riesgo de desarrollar adenomas y cáncer colorrectal. Con la evidencia científica disponible, queda justificada la necesidad de más estudios que evalúen el efecto protector de la aspirina u otros AINEs como medida preventiva del cáncer de colon, que definan la dosis mínima eficaz, la edad a la que comenzar el tratamiento, la duración más conveniente del mismo y las subpoblaciones para las que los beneficios de la quimioprofilaxis superan los posibles efectos adversos.Descargas
Citas
(1) La situación del cáncer en España (1975-2006) Centro nacional de epidemiología. Instituto de Salud Carlos III. Madrid, junio 2009.
(2) Alonso Sánchez A, Moreno S, Valiente A, Artigas M, Pérez-Juana A and Ramos-Arroyo MA. Genetic mechanism in the hereditay predisposition to colorectal cancer. An. Sist. Sanit. Navar. 2006; 29 (1): 59-76.
https://doi.org/10.4321/S1137-66272006000100006
(3) Betés, MT; Carretero, C; Muñoz Navas, MA. Evidencia científica en cribado del cáncer colorrectal. Manual de actuación. Madrid: IM & C; 2006.
(4) Zubiarre L, Bujanda Fernández de Pierola L. Aspirina en la prevención del cáncer colorrectal. Gastroenterol Hepatol 2011.
https://doi.org/10.1016/j.gastrohep.2011.01.004
(5) Chan, AT. NSAIDs (including aspirin): Role in prevention of colorectal cancer. Uptodate. Sept 2011.
(6) Benamouzig R, Uzzan B, Martin A, Deyra J, Little J, Girard B et al. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. GUT 2010; 59: 622-629.
https://doi.org/10.1136/gut.2008.175406
(7) Dubé, C, Rostom, A, Lewin, G, Tsertsvadze A, Barrowman N, Code C et al. The use of aspirin for primary prevention of colorectal cancer: a sistematic review prepared for the US Preventive Services Task Force. Ann Intern Med 2007; 146:365-375.
https://doi.org/10.7326/0003-4819-146-5-200703060-00009
(8) Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899.
https://doi.org/10.1056/NEJMoa021735
(9) Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890.
https://doi.org/10.1056/NEJMoa021633
(10) Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR, uk Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134: 29-38.
https://doi.org/10.1053/j.gastro.2007.10.014
(11) Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125: 328-336.
https://doi.org/10.1016/S0016-5085(03)00887-4
(12) Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-266.
https://doi.org/10.1093/jnci/djn485
(13) Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE et al. Low dose of aspirin in the primary prevention of cancer: the Women's Health Study: a randomiced controlled trial. JAMA 2005; 294: 45-55.
https://doi.org/10.1001/jama.294.1.47
(14) Gann PH, Manson JE, Glynn RJ, Buring JE and Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220-1224.
https://doi.org/10.1093/jnci/85.15.1220
(15) Stürmer T, Glynn RJ, Lee IM, Manson JE, Buring JE and Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from The Physicians'Health Study. Ann Intern Med 1998; 128: 713-720.
https://doi.org/10.7326/0003-4819-128-9-199805010-00003
(16) Rothwell P, Wilson M, Elwin CE, Norrving B, Algra A, Warlow P, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-1750.
https://doi.org/10.1016/S0140-6736(10)61543-7
(17) Burn J, Bishop DT, Mecklin JP, Macrae F, Möslein G, Olschwang S et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Eng J Med 2008; 359: 2567-2578.
https://doi.org/10.1056/NEJMoa0801297
(18) Burn J, Mathers JC, Gerdes AM, Bisgaard ML, Evans G, Eccles D et al. Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy. Hereditary Cancer in Clinical Practice 2010, 8 (Suppl 1):O5.
https://doi.org/10.1186/1897-4287-8-S1-O5
(19) Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. The Lancet 2011, oct 27.
(20) Giardello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-1316.
https://doi.org/10.1056/NEJM199305063281805
(21) Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. The effect of Celecoxib, a cyclooxygenase-2 inhibitor, in familiar adenomatous polyposis. N Eng J Med 2000; 342: 1946-1952.
https://doi.org/10.1056/NEJM200006293422603
(22) Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, and Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-923.
https://doi.org/10.1001/jama.294.8.914
(23) Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K and Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008; 134: 21-28.
https://doi.org/10.1053/j.gastro.2007.09.035
(24) Higuchi T, Iwana T, Yoshinaga K, Toyooka M, Taketo MM and Sugihara K. A randomized, doubled-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003; 9: 4756-4760.
(25) Bertagnolli MM, Eagle CJ, Zauber AG, Redtson M, Solomon SD, Kim K et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Eng J Med 2006; 355: 873-884.
https://doi.org/10.1056/NEJMoa061355
(26) Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The Lancet Oncol 2009; 10: 501-507.
https://doi.org/10.1016/S1470-2045(09)70035-X
(27) Antithrombotic Trialists'Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
https://doi.org/10.1136/bmj.324.7329.71
(28) O'Brien MJ, Winawer SJ, Zauber AG, Sternberg SS, Diaz B, Dickersin GR et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; Feb; 98 (2): 371-379.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2012 Anales del Sistema Sanitario de Navarra
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
